Staidson Beijing Biopharma (300204) - Net Assets
Based on the latest financial reports, Staidson Beijing Biopharma (300204) has net assets worth CN¥794.92 Million CNY (≈ $116.32 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.28 Billion ≈ $187.45 Million USD) and total liabilities (CN¥486.07 Million ≈ $71.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Staidson Beijing Biopharma to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥794.92 Million |
| % of Total Assets | 62.06% |
| Annual Growth Rate | 19.26% |
| 5-Year Change | -47.98% |
| 10-Year Change | -57.95% |
| Growth Volatility | 130.11 |
Staidson Beijing Biopharma - Net Assets Trend (2007–2025)
This chart illustrates how Staidson Beijing Biopharma's net assets have evolved over time, based on quarterly financial data. See Staidson Beijing Biopharma defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Staidson Beijing Biopharma (2007–2025)
The table below shows the annual net assets of Staidson Beijing Biopharma from 2007 to 2025. For live valuation and market cap data, see 300204 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥806.72 Million ≈ $118.05 Million |
-12.00% |
| 2024-12-31 | CN¥916.76 Million ≈ $134.15 Million |
-10.18% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.36 Million |
-24.61% |
| 2022-12-31 | CN¥1.35 Billion ≈ $198.11 Million |
-12.70% |
| 2021-12-31 | CN¥1.55 Billion ≈ $226.92 Million |
-2.32% |
| 2020-12-31 | CN¥1.59 Billion ≈ $232.30 Million |
-2.92% |
| 2019-12-31 | CN¥1.64 Billion ≈ $239.29 Million |
-33.47% |
| 2018-12-31 | CN¥2.46 Billion ≈ $359.66 Million |
+11.25% |
| 2017-12-31 | CN¥2.21 Billion ≈ $323.30 Million |
+15.18% |
| 2016-12-31 | CN¥1.92 Billion ≈ $280.70 Million |
+13.93% |
| 2015-12-31 | CN¥1.68 Billion ≈ $246.39 Million |
+11.19% |
| 2014-12-31 | CN¥1.51 Billion ≈ $221.60 Million |
+15.25% |
| 2013-12-31 | CN¥1.31 Billion ≈ $192.28 Million |
+5.90% |
| 2012-12-31 | CN¥1.24 Billion ≈ $181.57 Million |
+12.59% |
| 2011-12-31 | CN¥1.10 Billion ≈ $161.27 Million |
+562.99% |
| 2010-12-31 | CN¥166.23 Million ≈ $24.32 Million |
+38.85% |
| 2009-12-31 | CN¥119.72 Million ≈ $17.52 Million |
+90.58% |
| 2008-12-31 | CN¥62.82 Million ≈ $9.19 Million |
+85.46% |
| 2007-12-31 | CN¥33.87 Million ≈ $4.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Staidson Beijing Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46999492913.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.32 Billion | 160.49% |
| Total Equity | CN¥820.78 Million | 100.00% |
Staidson Beijing Biopharma Competitors by Market Cap
The table below lists competitors of Staidson Beijing Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Merit Interactive Network Technology Co Ltd Class A
SHE:300766
|
$1.41 Billion |
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
$1.41 Billion |
|
Ecovyst Inc
NYSE:ECVT
|
$1.41 Billion |
|
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
|
$1.41 Billion |
|
Perrigo Company PLC
NYSE:PRGO
|
$1.41 Billion |
|
Sitio Royalties Corp.
NYSE:STR
|
$1.41 Billion |
|
BGF Retail Co Ltd
KO:282330
|
$1.40 Billion |
|
Zhongli Science and Technology Group Co Ltd
SHE:002309
|
$1.40 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Staidson Beijing Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 929,233,931 to 820,780,796, a change of -108,453,135 (-11.7%).
- Net loss of 77,763,331 reduced equity.
- Dividend payments of 1,085,619 reduced retained earnings.
- Other comprehensive income decreased equity by 415,726,391.
- Other factors increased equity by 386,122,206.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-77.76 Million | -9.47% |
| Dividends Paid | CN¥1.09 Million | -0.13% |
| Other Comprehensive Income | CN¥-415.73 Million | -50.65% |
| Other Changes | CN¥386.12 Million | +47.04% |
| Total Change | CN¥- | -11.67% |
Book Value vs Market Value Analysis
This analysis compares Staidson Beijing Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 175.03x to 11.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.11 | CN¥20.11 | x |
| 2008-12-31 | CN¥0.20 | CN¥20.11 | x |
| 2009-12-31 | CN¥0.36 | CN¥20.11 | x |
| 2010-12-31 | CN¥0.47 | CN¥20.11 | x |
| 2011-12-31 | CN¥2.55 | CN¥20.11 | x |
| 2012-12-31 | CN¥2.65 | CN¥20.11 | x |
| 2013-12-31 | CN¥2.81 | CN¥20.11 | x |
| 2014-12-31 | CN¥3.21 | CN¥20.11 | x |
| 2015-12-31 | CN¥3.55 | CN¥20.11 | x |
| 2016-12-31 | CN¥3.99 | CN¥20.11 | x |
| 2017-12-31 | CN¥4.62 | CN¥20.11 | x |
| 2018-12-31 | CN¥5.13 | CN¥20.11 | x |
| 2019-12-31 | CN¥3.59 | CN¥20.11 | x |
| 2020-12-31 | CN¥3.34 | CN¥20.11 | x |
| 2021-12-31 | CN¥3.27 | CN¥20.11 | x |
| 2022-12-31 | CN¥2.82 | CN¥20.11 | x |
| 2023-12-31 | CN¥2.15 | CN¥20.11 | x |
| 2024-12-31 | CN¥1.92 | CN¥20.11 | x |
| 2025-12-31 | CN¥1.72 | CN¥20.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Staidson Beijing Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -35.31%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.54x
- Recent ROE (-9.47%) is below the historical average (4.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 11.11% | 15.61% | 0.29x | 2.43x | CN¥374.29K |
| 2008 | 26.14% | 32.26% | 0.55x | 1.47x | CN¥10.14 Million |
| 2009 | 29.54% | 39.97% | 0.59x | 1.24x | CN¥23.39 Million |
| 2010 | 34.59% | 44.85% | 0.48x | 1.59x | CN¥40.88 Million |
| 2011 | 9.46% | 50.66% | 0.18x | 1.04x | CN¥-5.95 Million |
| 2012 | 12.91% | 28.81% | 0.39x | 1.15x | CN¥36.16 Million |
| 2013 | 8.34% | 12.27% | 0.57x | 1.19x | CN¥-21.83 Million |
| 2014 | 12.90% | 17.87% | 0.60x | 1.20x | CN¥43.84 Million |
| 2015 | 12.68% | 16.91% | 0.60x | 1.24x | CN¥44.55 Million |
| 2016 | 13.53% | 18.33% | 0.60x | 1.24x | CN¥67.06 Million |
| 2017 | 11.91% | 18.95% | 0.53x | 1.19x | CN¥42.09 Million |
| 2018 | 5.45% | 16.63% | 0.29x | 1.13x | CN¥-111.73 Million |
| 2019 | 1.67% | 4.13% | 0.36x | 1.14x | CN¥-136.22 Million |
| 2020 | -8.38% | -31.28% | 0.23x | 1.17x | CN¥-291.77 Million |
| 2021 | -8.86% | -23.52% | 0.32x | 1.18x | CN¥-292.47 Million |
| 2022 | -14.55% | -35.89% | 0.33x | 1.23x | CN¥-332.39 Million |
| 2023 | -39.08% | -109.53% | 0.27x | 1.31x | CN¥-500.96 Million |
| 2024 | -15.59% | -44.59% | 0.28x | 1.24x | CN¥-237.77 Million |
| 2025 | -9.47% | -35.31% | 0.17x | 1.54x | CN¥-159.84 Million |
Industry Comparison
This section compares Staidson Beijing Biopharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,796,003,820
- Average return on equity (ROE) among peers: -1.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Staidson Beijing Biopharma (300204) | CN¥794.92 Million | 11.11% | 0.61x | $1.41 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $89.81 Million | 2.75% | 1.57x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $205.14 Million | 10.08% | 0.94x | $1.58 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $144.30 Million | -93.32% | 1.86x | $380.55 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $156.83 Million | 24.69% | 0.38x | $473.06 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.59 Billion |
| Hualan Biological EngineeringInc (002007) | $550.80 Million | 9.54% | 0.27x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.12 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $11.49 Billion | 5.29% | 0.03x | $4.56 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.51 Billion | 3.27% | 0.28x | $507.88 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.89 Billion | 15.89% | 0.21x | $1.66 Billion |
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mou… Read more